
    
      OUTLINE: This is a dose-escalation study of 211At-OKT10-B10.

      Patients receive 211At-OKT10-B10 intravenously (IV) continuously on days -7 to -4 and
      melphalan via infusion on day -2. Patients then undergo peripheral blood stem cell (PBSC)
      transplantation on day 0.

      After completion of study treatment, patients are followed for 30 days, between 80 and 90
      days, at 6, 9, 12, 18, and 24 months, and then annually thereafter.
    
  